Monitor upcoming medical conference presentations (Q4 2026) for detailed data and any subsequent guidance updates. The results reinforce ILUVIEN's clinical value in chronic NIU-PS, potentially leading to increased prescription volume.
Drug in focus
ANIP drug pipeline →ILUVIEN
● Neutral Named in this press release- Impact
- Phase
- Approved (Phase 4 SYNCHRONICITY data reported July 2026)
- Time to market
- Already approved and marketed (FDA-approved September 2014 for DME; label expanded March 2025 for NIU-PS uveitis)
- Next catalyst
- None dated
What to watchILUVIEN is a steady commercial asset within ANI's larger Rare Disease transition story. The positive July 2026 Phase 4 SYNCHRONICITY data supports the uveitis label expansion's real-world use, but the stock's bigger drivers are Cortrophin Gel growth and overall margin expansion. Watch quarterly sales trends for ILUVIEN against the $78M-$83M 2026 guidance.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 13 $81.08entry
- T+1 · 4mo ago −0.65%α −1.01% · $80.55
- T+5 · 4mo ago −2.32%α −1.53% · $79.20
- T+20 · 3mo ago −6.56%α −9.75% · $75.76
- T+60 · 7w ago −11.79%α −15.78% · $71.52
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ANI Pharmaceuticals reported positive topline Phase 4 data for ILUVIEN in chronic non-infectious uveitis affecting the posterior segment (NIU-PS), meeting both co-primary endpoints with statistical significance. The results support the drug's safety and efficacy in a real-world setting, potentially boosting commercial uptake.
Key Facts
- SYNCHRONICITY trial met co-primary endpoints: mean change in BCVA (+3.6 letters, p<0.0077) and CST (-157.5 microns, p<0.0001) at 6 months.
- Safety profile consistent with prior ILUVIEN trials; 29% treatment-related TEAEs, most common ocular hypertension (6%) and cataract (5%).
- ILUVIEN already FDA-approved for DME (2014) and expanded for chronic NIU-PS (2025); this Phase 4 data adds real-world evidence.
- Detailed results to be presented at medical conferences in Q4 2026.
Financial Impact
Positive data could drive increased adoption of ILUVIEN for chronic NIU-PS, supporting revenue growth from the Rare Disease segment, but no revenue guidance provided.
Risk Factors
- Competition from other uveitis treatments; potential safety signals as real-world use expands.
- Commercial execution risk in building out the rare disease sales force.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3326047 |
Track record
34 reports on ANIP
4 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
- Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
- Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
- Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
- Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
- Nov 5, 202617d ago 8-K Bullish 6/10 No price data
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers